Abstract #4286

Developing CEST-detectable liposomal hydrogel for monitoring local brain tumor treatment

Se Weon Park^1,2, Joseph H.C Lai¹, Xiongqi Han³, Jianpan Huang¹, Peng Xiao¹, and Kannie W.Y. Chan^1,4,5

¹Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, Hong Kong, ²Hong Kong Centre for Cerebro-Cardiovascular Health Engineering (COCHE), Hong Kong, Hong Kong, ³SiBionics, Shenzhen, China, ⁴Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States, ⁵City University of Hong Kong Shenzhen Research Institute, Shenzhen, China

Synopsis

Glioblastoma is a malignant form of brain tumors, which has a high recurrence even with combined treatments. Here, we developed anti-cancer drugs loaded liposomal hydrogels for sustainable drug release to treat brain tumors locally under MRI guidance. These anti-cancer drugs are CEST-detectable. We observed a continuous decrease in tumor size and CEST contrast at 3.5 and -3.5 ppm compared to control group, where drug-free liposomal hydrogel was injected. The therapeutic efficacy of local drug delivery using liposomal hydrogel was evidenced and can be monitored using CEST multiple-contrast approach. This could serve a robust theranostic application for local brain tumor treatment.

This abstract and the presentation materials are available to members only; a login is required.

Join Here